Lipoprotein News and Research

RSS

A lipoprotein is a biochemical assembly that contains both proteins and lipids. The lipids or their derivatives may be covalently or non-covalently bound to the proteins.

Lean beef good for teenagers

Diets rich in lean beef can help teenagers maintain their levels of useable iron, teach important balanced eating habits and dispel rumors that all healthy diets are challenging and lack taste, according to a researcher in the University of Iowa College of Public Health.

28 Apr 2004

Women who have migraines with aura have a more than 50 percent increased risk of total stroke and 70 percent increase of ischemic stroke

Women who have migraines with aura have a more than 50 percent increased risk of total stroke and 70 percent increase of ischemic stroke compared to those without migraines, according to research that will be presented at the American Academy of Neurology 56th Annual Meeting

27 Apr 2004

Dieting greatly reduces risk of heart attack, stroke and diabetes

People who severely restrict their caloric intake drastically reduce their risk of developing diabetes or clogged arteries, the precursor to a heart attack or stroke. In fact, according to researchers at Washington University School of Medicine in St Louis, some risk factors were so low they were comparable to those of people decades younger.

20 Apr 2004

Strict dieting can dramatically reduce the risk of heart disease

19 Apr 2004

First Approval in Europe of Ezetimibe/Simvastatin for treatment of elevated cholesterol

Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad’ cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU’s mutual recognition procedure.

4 Apr 2004

Human Genome Sciences can begin cardiovascular disease research

Human Genome Sciences, Inc.announced today that it has received a clinical development milestone payment from its partner, GlaxoSmithKline, related to the initiation of Phase 1 clinical trials of 677116 for the treatment of cardiovascular disease. 677116 is a small-molecule inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme associated with the formation of atherosclerotic plaques.

30 Mar 2004

Research provides better understanding of lipodystrophies disorders

More than a decade of work conducted by UT Southwestern Medical Center at Dallas researchers has led to a better understanding of the underlying causes of lipodystrophies - disorders characterized by the selective loss of fat tissues, resulting in metabolic complications, such as severe diabetes and high blood cholesterol levels.

22 Mar 2004

AMT Obtains Orphan Drug Designation for Its LPL Gene Therapy Product

AMT today announced that its adeno-associated viral vector (AAV) expressing lipoprotein lipase (LPL) product has been designated as an orphan medicinal product for the treatment of LPL deficiency by the European Commission. This decision follows a positive recommendation by the European Agency for the Evaluation of Medicinal Products.

22 Mar 2004